IBSA Reacquires Commercial Rights to the Flector Brand in the US
I
BSA Pharma Inc. has taken back marketing and distribution rights for Flector (diclofenac epolamine) topical system 1.3% from Pfizer as of January 1st, 2021.
With the return of the commercial rights of Flector, a product that IBSA has developed, IBSA now offers two prescription topical drugs to treat acute pain due to minor strains, sprains, and contusions. Both Flector and Licart are manufactured under strict IBSA Quality System control.
In 2020, IBSA introduced Licart (diclofenac epolamine) topical system 1.3%, the only FDA-approved once-a-day topical NSAID therapy with next- generation patch technology.
IBSA Pharma Inc is Now Marketing and Distributing Flector in the US
As of January 2021, marketing rights for Flector have reverted to IBSA, the originator of the product. Flector is supported by more than 30 years of clinical experience and has been proven to deliver relief of acute pain for a wide variety of patients and pain sites with twice-a-day dosing. ¹ A promotional program is available to support Flector prescribers and patients with product samples, literature, and improved patient savings programs. IBSA's decision to lower the price of Flector and implement significant patient savings programs means that, for many patients, branded Flector will be available at the lowest cost of any diclofenac topical systems with the exception of Licart. Information about Flector and Flector savings programs can be found at www.Flector.com.
Licart, Next-Generation Topical NSAID Therapy, Now Available by IBSA
At the end of 2020, IBSA also launched Licart (diclofenac epolamine) topical system 1.3% for the relief of acute pain associated with minor strains, sprains, and contusions. Licart is the first and only once-a-day topical nonsteroidal anti-inflammatory drug (NSAID) therapy approved by the FDA. Thanks to its patented next-generation patch technology which combines two innovative drug delivery systems, Licart's improved skin permeability delivers diclofenac epolamine, a widely used NSAID. This allows a fast onset and sustained pain relief. Licart is proven to provide significant pain relief within 1-3 hours after application and continues to relieve pain for 24 hours.²
Licart is the latest product to be launched by IBSA Pharma Inc., a fully owned subsidiary of IBSA Institut Biochimique SA which is headquartered in Lugano, Switzerland. IBSA is a world leader in topical pain management.
Like Flector, IBSA supports Licart with patient starter kits, product literature and patient savings programs. Most commercially insured patients using the Licart Copay Card can pay as little as $0 per month of therapy. Patients with or without commercial insurance coverage for Licart can use the Licart Direct Program, a network of mail order pharmacies, to get the lowest cash price available for Licart. Licart is also available on the TriCare formulary. Additional details about Licart and Licart patient savings programs can be found at www.Licart.com.
We are excited to have Flector, the original diclofenac topical system and only branded diclofenac topical system indicated for children 6 years and older, back in the IBSA product portfolio, stated Aldo Donati, President and CEO of IBSA Pharma. We are also excited to offer Licart, a product that features patented next-generation patch technology and is the only FDA approved once-a-day topical treatment for acute pain due to minor strains, sprains, and contusions. Licart and Flector, along with IBSA's unique products for hypothyroidism - Tirosint www.tirosint.com and Tirosint-SOL www.tirosintsol.com - allow us to offer patients and caregivers a broader range of unique therapeutic formulations for some of the most common health problems encountered in clinical practice.
✔️ IBSA Reacquires Commercial Rights to the Flector Brand in the US
💕 Found this article helpful? Spread the word and support us!